FDA's oncology adcomm votes against Amgen's confirmatory data for Lumakras in certain types of NSCLC
The FDA and its oncology advisory committee raised lots of questions on whether Amgen’s confirmatory trial is enough to convert an accelerated approval to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
